Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11037581 | 0.98 | CES2 (0.52) | CES2CES1POLBELANEHPGD | |
| SCHEMBL14614307 | 0.90 | CES2 (0.56) | CES2CES1POLBELANERAB9A | |
| SCHEMBL17779987 | 0.85 | KMO (0.50) | HPGDKMOKCNK3KCNK9 | |
| SCHEMBL16109370 | 0.81 | KMT2A (0.54) | CES2CES1POLBRAB9AGAA | |
| SCHEMBL27566019 | 0.81 | POLB (0.47) | CES2CES1POLBELANEHPGD | |
| Benzoic Acid SCHEMBL31356467 | 0.80 | SRD5A2 (0.58) | CES2CES1POLBELANEHPGD | |
| Benzoic Acid SCHEMBL5788950 | 0.80 | SRD5A2 (0.58) | CES2CES1POLBELANEHPGD | |
| SCHEMBL1427963 | 0.79 | SRD5A2 (0.67) | POLBELANEHPGDKCNK3KCNK9 | |
| SCHEMBL15155929 | 0.79 | SRD5A2 (0.67) | POLBELANEHPGDKCNK3KCNK9 | |
| SCHEMBL33443 | 0.79 | SRD5A2 (0.67) | POLBELANEHPGDKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7695863-B2 | rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive | UBE INDUSTRIES, LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20080102377-A1 | rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive | UBE INDUSTRIES, LTD (JP) | 2008-05-01 | — | — | US | disclosed |
| US-7189724-B2 | Quinoxaline derivatives having antiviral activity | VALEANT RESEARCH AND DEVELOPMENT (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189724-B2 | Quinoxaline derivatives having antiviral activity | VALEANT RESEARCH AND DEVELOPMENT (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2007016012-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-3968121-A | 1,2-Diphenyl-4,5,6,7-tetrahydroindoles | STERLING DRUG INC. (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | BACE1, BACE2, APP | CES2 1190/4885CES1 729/4885POLB 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.